PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. (Nasdaq: PRDS) is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies, including treatments targeting SARS-CoV-2. The company went public through a SPAC merger with LifeSci Acquisition 2 Corp, a blank-check vehicle sponsored by LifeSci Capital LLC that completed its IPO in 2021. Operating in the biopharmaceutical sector, Pardes centered its pipeline on small-molecule protease inhibitors intended to address acute viral infections. The May 2021 Form 10-Q filing reflects the company's early post-combination reporting period as it transitioned from development-stage operations to a publicly traded entity. Visit SpacDesk and sign up for full data on PRDS, including deal terms, timeline milestones, and sponsor history.